1-7 of 7
Ibraheem Othman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Ibrutinib in Elderly Patients with Chronic Lymphocytic Leukemia: Adverse Event Incidence, Management, and Outcome in a Canadian Real-World Setting

Ibraheem Othman, Seyedeh Zahra (Mona) Moossavi, Samaneh Bayati, Yi Sin Chang, Shubrandu Sanjoy, Karolina Grzyb, Eric Sy, Kayla Cropper, Sandy Kassir, Waleed Sabry
Journal: Blood
Blood (2024) 144 (Supplement 1): 6796.
https://doi.org/10.1182/blood-2024-208893
Published: 2024
Journal Articles

Efficacy and Tolerance of Isatuximab, Cyclophosphamide, Bortezomib, and Dexamethasone (Isa-CBD) Induction Chemotherapy in Newly Diagnosed, Transplant Eligible Multiple Myeloma: Report of the Phase 2 Multi-Centre, Open Label Canadian Myeloma Research Group (CMRG)-008 Prospective Clinical Trial

Rami Kotb, Darrell White, Sita Bhella, Arleigh McCurdy, Irwindeep Sandhu, Hira Mian, Julie Stakiw, Ibraheem Othman, Jiandong Su, Aniba Khan, Engin Gul, Donna Reece
Journal: Blood
Blood (2023) 142 (Supplement 1): 4751.
https://doi.org/10.1182/blood-2023-190168
Published: 2023
Journal Articles

Prevention of Ocular Toxicity Using Protective Contact Lenses in Multiple Myeloma Patients Receiving Belantamab Mafodotin, Pomalidomide and Dexamethasone: A Sub-Study of the Cmrg-007 Trial

Martha L Louzada, Donna E. Reece, Arleigh McCurdy, Rami Kotb, Ibraheem Othman, Hira Mian, Toni Lin, Michael P Chu, Darrell White, Stephen Parkin, Engin Gul, Aniba Khan, Suzanne Trudel
Journal: Blood
Blood (2023) 142 (Supplement 1): 4756.
https://doi.org/10.1182/blood-2023-174993
Published: 2023
Journal Articles

Retrospective Data Collection Study: Hematologic Toxicities with Immunotherapy in Cancer Patients at the Allan Blair Cancer Centre

Amani Khan, Sandy Kassir, Osama Souied, Ibraheem Othman
Journal: Blood
Blood (2022) 140 (Supplement 1): 13171.
https://doi.org/10.1182/blood-2022-162989
Published: 2022
Journal Articles

Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone Demonstrates Durable Responses in Triple Class Exposed/Refractory Multiple Myeloma

Suzanne Trudel, Arleigh McCurdy, Molei Fu, Heather J. Sutherland, Martha L Louzada, Michael P. Chu, Darrell J White, Hira S Mian, Rami Kotb, Ibraheem Othman, Moustafa Kardjadj, Engin Gul, Donna E. Reece
Journal: Blood
Blood (2022) 140 (Supplement 1): 7306–7307.
https://doi.org/10.1182/blood-2022-160445
Published: 2022
Journal Articles

Pembrolizumab Added to First-Line Cyclophosphamide, Bortezomib and Dexamethasone in Newly Diagnosed Transplant Non-Eligible Myeloma Patients: A Phase 2A Open Label, Multi Centre Study

Rami Kotb, Engin Gul, Nizar Abdel-Samad, Ibraheem Othman, Michel Pavic, Donna E. Reece
Journal: Blood
Blood (2021) 138 (Supplement 1): 4768.
https://doi.org/10.1182/blood-2021-153897
Published: 2021
Journal Articles

Part 1 Results of a Dose-Finding Study of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM)

Suzanne Trudel, Arleigh McCurdy, Heather J. Sutherland, Martha L Louzada, Christopher P. Venner, Hira S Mian, Rami Kotb, Ibraheem Othman, Fernando Camacho, Engin Gul, Donna E. Reece, Darrell J White, Molei Fu
Journal: Blood
Blood (2021) 138 (Supplement 1): 1653.
https://doi.org/10.1182/blood-2021-147101
Published: 2021